Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
about
Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adultsTreatment of Kaposis sarcoma in HIV-1 infected individuals with emphasis on resource poor settingsCardiotoxicity in childhood cancer survivors: strategies for prevention and managementDepressogenic effects of medications: a reviewLiposome-based drug delivery in breast cancer treatmentTreating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristineCase Report: No Response to Liposomal Daunorubicin in a Patient with Drug-Resistant HIV-Associated Visceral LeishmaniasisNanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitorsClinical Translation of Nanomedicine.Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study.Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysisState-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicinesUpdate on KSHV epidemiology, Kaposi Sarcoma pathogenesis, and treatment of Kaposi Sarcoma.Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.Delivering nanomedicine to solid tumors.A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma.Liposomally targeted cytotoxic drugs for the treatment of cancer.Therapeutic approaches to AIDS-related malignancies.Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacyNovel pharmacological therapies for the treatment of AIDS-related Kaposi's sarcoma.Biological rationale for the design of polymeric anti-cancer nanomedicines.Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.Design considerations for nanotherapeutics in oncology.Radiolabeled liposome imaging determines an indication for liposomal anticancer agent in ovarian cancer mouse xenograft models.Trends in Kaposi's Sarcoma in Miami Beach from 1987 to 2007A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancerDelivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.Liposomal daunorubicin as treatment for Kaposi's sarcomaAnthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation.Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice.Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.Targeted therapy for Kaposi sarcoma.Targeted drug delivery strategies to treat lung metastasis.Hepatic Kaposi sarcoma: A case report and review of the literature.Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology.New drug targets in Kaposi sarcoma.Pharmacological management of Kaposi's sarcoma.
P2860
Q24193874-A3F70894-B64D-4A90-94E9-900B35EC1819Q24247970-93C631D4-E6DA-4B46-8F9B-A157DF3520D7Q24628695-68E5F604-E381-439F-990D-6C9A2BA04B48Q24635465-5DD35B8E-6375-4282-A385-AB403A7CE921Q24802484-83DFC435-DC65-47FC-8E2B-7479DD53703CQ27000078-CFF38A8D-D862-4A54-B25E-298D52175D3BQ28547477-67373736-600A-4FD3-8F69-795BA746EF61Q28818166-2DA9DCDF-8A11-4CE0-B274-1FD835823C4FQ30355939-8F4C8C1E-E1EA-4E13-A574-1A1E6B3F89FCQ30366990-54E706E9-5374-4EC6-9473-9BFF36907755Q33343690-F814A0BD-3116-42CB-BC7E-40253E85A4CAQ33404677-F7F917A0-B0CB-4037-8A9F-225672FBF488Q34045119-EDBF9B5A-097D-4463-BD86-A742D8615EB8Q34168712-6BAF1ADF-A436-4A97-A747-EC99093587E5Q34280875-781FF269-D839-485F-BA0A-B24FC31676ACQ34620787-C2005BA0-BC9E-43C5-819B-BF5652D8997CQ34726981-7BF45856-C31A-43D5-88F2-0C96EF86E06BQ34795330-7556A634-8B0A-4355-AB23-646996DF5A22Q35051019-63418166-ECAD-46BA-B781-CC7CCE982D42Q35551167-AED984D9-3AF0-42B6-937E-EED45445B99FQ35679856-A54BABC6-3F73-4877-960A-672959AF095FQ35779249-DCA60E60-CACE-4180-AEAF-E2FEF45E7444Q36160333-A6985376-41F5-4A1D-933F-5E7202D1E3A4Q36212921-874B3E61-DC4D-465B-99CA-B9A79D8EEBFDQ36236848-D7BB1A31-0DEF-4564-9D0B-FBB60EF74CDEQ36495946-293B179F-ADFA-4E7D-82F7-39770080AFC6Q36520006-54C1314A-04F1-437D-82B0-A92E04EDBA86Q36624187-5265576B-C75F-4F2F-B736-66444FC5C528Q36791673-82140876-432A-47AE-96EC-D722000AEB1EQ36988072-E681F717-6296-4AF4-873C-FAF713C8FDA0Q37004096-34552A12-D619-4BC1-853A-6F17BFBF6801Q37059896-9AC84CA6-99A4-4D72-90DD-B3F7CCD99592Q37467770-5F576D0A-EA8A-40FD-B107-330773E6E063Q37476252-F9F4E994-0FD2-406D-A8FB-F6CAF9370060Q37505000-850D2DE4-5D6C-4C9E-A6E8-241CFB9887ECQ37575499-B5EAE604-5C32-4778-9DFA-085E514A1973Q37628536-90FE4667-C7EE-45EC-B03C-B884FF561AEFQ37689857-F63698E8-18B9-4199-942A-9DDC47C19314Q37806235-350F5AAE-4017-45AD-8A51-931D28929CBFQ37868566-A2A9244F-15C5-4808-B008-1E429A915C63
P2860
Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
description
1996 nî lūn-bûn
@nan
1996 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Randomized phase III trial of ...... AIDS-related Kaposi's sarcoma.
@ast
Randomized phase III trial of ...... AIDS-related Kaposi's sarcoma.
@en
Randomized phase III trial of ...... AIDS-related Kaposi's sarcoma.
@nl
type
label
Randomized phase III trial of ...... AIDS-related Kaposi's sarcoma.
@ast
Randomized phase III trial of ...... AIDS-related Kaposi's sarcoma.
@en
Randomized phase III trial of ...... AIDS-related Kaposi's sarcoma.
@nl
prefLabel
Randomized phase III trial of ...... AIDS-related Kaposi's sarcoma.
@ast
Randomized phase III trial of ...... AIDS-related Kaposi's sarcoma.
@en
Randomized phase III trial of ...... AIDS-related Kaposi's sarcoma.
@nl
P2093
P1476
Randomized phase III trial of ...... AIDS-related Kaposi's sarcoma.
@en
P2093
D T Scadden
F Shepherd
G Gonzales
G M Mukwaya
I Silverberg
J H von Roenn
P304
P356
10.1200/JCO.1996.14.8.2353
P407
P577
1996-08-01T00:00:00Z